SAN DIEGO, Aug. 10 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX) announced today results for its first fiscal quarter ended June 30, 2009. Net sales increased 22% for the quarter to $1,702,000 from the $1,394,000 reported for the same period last year.
Net loss for the quarter was ($415,000) or ($.04) per share compared to a net profit for the same period of the prior fiscal year of $587,000 or $0.05 per share. The prior fiscal year period was positively impacted by a one time settlement of $1,785,000.
Commenting on the results of the first quarter, Mr. William Spencer, Imagenetix Chief Executive Officer said, "We were encouraged by the increase in sales of our weight loss product and of our own branded product, InflameAway Celadrin, which is beginning to be well received in the food, drug and mass market segments. However, we were disappointed that sales of our raw material to wholesalers and distributors came in lower compared to the previous year as they became negatively impacted by current economic conditions. We continue to expand advertising and marketing to assure increased awareness and acceptability of InflameAway Celadrin. We anticipate this marketing program for the mass market segment to continue to result in improved sales during the balance of our current fiscal year."
Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partner
|SOURCE Imagenetix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved